These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10328989)

  • 21. The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.
    Frassoldati A; Guarneri V; Conte P
    Cancer Biol Ther; 2009 Aug; 8(15):1456-8. PubMed ID: 19617703
    [No Abstract]   [Full Text] [Related]  

  • 22. Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer.
    al-Alwan NA; al-Kubaisy W; al-Rawaq K
    East Mediterr Health J; 2000; 6(2-3):475-82. PubMed ID: 11556039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
    Kijima I; Itoh T; Chen S
    J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen, raloxifene, and the prevention of breast cancer.
    Jordan VC; Morrow M
    Endocr Rev; 1999 Jun; 20(3):253-78. PubMed ID: 10368771
    [No Abstract]   [Full Text] [Related]  

  • 25. [Tamoxifen: modern drug therapy of estrogen-dependent breast tumors].
    Jovanović-Mićić D; Beleslin DB; Nikolić SS
    Med Pregl; 1996; 49(7-8):287-90. PubMed ID: 8926945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of novel oestrogen-receptor antagonists.
    Wakeling AE; Bowler J
    Biochem Soc Trans; 1991 Nov; 19(4):899-901. PubMed ID: 1794580
    [No Abstract]   [Full Text] [Related]  

  • 27. The influence of tamoxifen on the maturation index of vaginal epithelium.
    Friedrich M; Mink D; Villena-Heinsen C; Woll-Hermann A; Wagner S; Schmidt W
    Clin Exp Obstet Gynecol; 1998; 25(4):121-4. PubMed ID: 9987567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular aspects of different mechanisms of tamoxifen resistance].
    Bachmann-Moisson N; Barberi-Heyob M; Merlin JL
    Bull Cancer; 1997 Jan; 84(1):69-75. PubMed ID: 9180863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiestrogens, antiandrogens.
    Borvendég J; Hermann I; Csuka O
    Acta Physiol Hung; 1996; 84(4):405-6. PubMed ID: 9328614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Droloxifene--a novel antiestrogen in endocrine dependent human tumors xenotransplanted into nude mice.
    Stelzer P; Staab HJ; Kömpf J
    Strahlenther Onkol; 1989 Jul; 165(7):559-60. PubMed ID: 2749496
    [No Abstract]   [Full Text] [Related]  

  • 32. Tamoxifen in early breast cancer.
    Arriagada R
    Lancet; 1998 Aug; 352(9125):403-4. PubMed ID: 9717953
    [No Abstract]   [Full Text] [Related]  

  • 33. The regulation of estrogen receptor expression and function in human breast cancer.
    Ferguson AT; Lapidus RG; Davidson NE
    Cancer Treat Res; 1998; 94():255-78. PubMed ID: 9587692
    [No Abstract]   [Full Text] [Related]  

  • 34. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
    Sgroi DC; Haber DA; Ryan PD; Ma XJ; Erlander MG
    Cancer Cell; 2004 Nov; 6(5):445. PubMed ID: 15542428
    [No Abstract]   [Full Text] [Related]  

  • 35. Tamoxifen in early breast cancer.
    Bryce CJ
    Lancet; 1998 Aug; 352(9125):403. PubMed ID: 9717952
    [No Abstract]   [Full Text] [Related]  

  • 36. Estrogen receptor: a never ending story?
    Wolff AC; Dowsett M
    J Clin Oncol; 2011 Aug; 29(22):2955-8. PubMed ID: 21709205
    [No Abstract]   [Full Text] [Related]  

  • 37. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ; Craig Jordan V
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
    Planas-Silva MD; Waltz PK; Kilker RL
    J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.